Home>>Signaling Pathways>> DNA Damage/DNA Repair>> PARP>>ME0328


Catalog No.GC13419

PARP inhibitor,potent and selective

Products are for research use only. Not for human use. We do not sell to patients.

ME0328 Chemical Structure

Cas No.: 1445251-22-8

Size Price Stock Qty
10mM (in 1mL DMSO)
In stock
In stock
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ME0328 is a potent and selective inhibitor of PARP with IC50 value of 0.89 and 6.3 μM for PARP3 and PARP1, respectively [1].

Poly (ADP-ribose) polymerase (PARP) is a family of proteins mainly involved in programmed cell death and DNA repair. The overactivation of PARP may reduce the stores of cellular NAD+ and induce ATP depletion and cell death.

ME0328 is a potent and selective PARP inhibitor. ME0328 selectively inhibited ADP-ribosyltransferase-3/poly(ADP-ribose) polymerase-3 (ARTD3) with IC50 value of 0.89 μM and inhibited ARTD1 and ARTD2 with IC50 values of 6.3 and 10.8 μM, respectively. In human alveolar basal epithelial (A549) cells, treatment with ME0355 (10 μM) followed by γ-irradiation significantly delayed γH2AX-foci resolution in a concentration-dependent way, which suggested that ME0328 inhibited ARTD3 in cells. In nonirradiated human A549 and mouse MRC5 cells, ME0328 (10 μM) did not exhibit toxicity [1].

[1].  Lindgren AE, Karlberg T, Thorsell AG, et al. PARP inhibitor with selectivity toward ADP-ribosyltransferase ARTD3/PARP3. ACS Chem Biol, 2013, 8(8): 1698-1703.


Review for ME0328

Average Rating: 5 ★★★★★ (Based on Reviews and 10 reference(s) in Google Scholar.)

5 Star
4 Star
3 Star
2 Star
1 Star
Review for ME0328

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.